Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15713401rdf:typepubmed:Citationlld:pubmed
pubmed-article:15713401lifeskim:mentionsumls-concept:C0040877lld:lifeskim
pubmed-article:15713401lifeskim:mentionsumls-concept:C0378796lld:lifeskim
pubmed-article:15713401lifeskim:mentionsumls-concept:C0268563lld:lifeskim
pubmed-article:15713401lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:15713401lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:15713401lifeskim:mentionsumls-concept:C1152564lld:lifeskim
pubmed-article:15713401lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:15713401lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:15713401pubmed:issue5lld:pubmed
pubmed-article:15713401pubmed:dateCreated2005-2-16lld:pubmed
pubmed-article:15713401pubmed:abstractTextA versatile synthesis of the suitably functionalized pyrrolo[2,1-f][1,2,4]triazine nucleus is described. SAR at the C-5 and C-6 positions of the 4-(3-hydroxy-4-methylphenylamino)pyrrolo[2,1-f][1,2,4]triazine template led to compounds with good in vitro potency against VEGFR-2 kinase. Glucuronidation of the phenol group is mitigated by incorporation of a basic amino group on the C-6 side chain of the pyrrolotriazine nucleus.lld:pubmed
pubmed-article:15713401pubmed:languageenglld:pubmed
pubmed-article:15713401pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713401pubmed:citationSubsetIMlld:pubmed
pubmed-article:15713401pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713401pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713401pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713401pubmed:statusMEDLINElld:pubmed
pubmed-article:15713401pubmed:monthMarlld:pubmed
pubmed-article:15713401pubmed:issn0960-894Xlld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:HuntJohn TJTlld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:QianLigangLlld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:CaiZhen-WeiZWlld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:VyasViralVlld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:FuraAberraAlld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:BhideRajeev...lld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:FargnoliJosep...lld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:MortilloSteve...lld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:WautletBarriBlld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:TokarskiJohnJlld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:BorzilleriRob...lld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:EllisChristop...lld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:GerhardtTracy...lld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:GoyalBinduBlld:pubmed
pubmed-article:15713401pubmed:authorpubmed-author:ZhengXiopingXlld:pubmed
pubmed-article:15713401pubmed:issnTypePrintlld:pubmed
pubmed-article:15713401pubmed:day1lld:pubmed
pubmed-article:15713401pubmed:volume15lld:pubmed
pubmed-article:15713401pubmed:ownerNLMlld:pubmed
pubmed-article:15713401pubmed:authorsCompleteYlld:pubmed
pubmed-article:15713401pubmed:pagination1429-33lld:pubmed
pubmed-article:15713401pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:meshHeadingpubmed-meshheading:15713401...lld:pubmed
pubmed-article:15713401pubmed:year2005lld:pubmed
pubmed-article:15713401pubmed:articleTitleSynthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.lld:pubmed
pubmed-article:15713401pubmed:affiliationDepartment of Oncology Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000, USA.lld:pubmed
pubmed-article:15713401pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:15713401lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15713401lld:pubmed